



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/195, 31/385</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/57627</b> <b>(43) International Publication Date:</b> 23 December 1998 (23.12.98)
<b>(21) International Application Number:</b> PCT/US98/12545 <b>(22) International Filing Date:</b> 16 June 1998 (16.06.98)  <b>(30) Priority Data:</b> 08/874,467                      16 June 1997 (16.06.97)                      US  <b>(71) Applicant:</b> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 5th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).  <b>(72) Inventors:</b> AMES, Bruce, N.; University of California, 401 Barker Hall, Berkeley, CA 94720-3202 (US). HAGEN, Tory, M.; University of California, 401 Barker Hall, Berkeley, CA 94720-3202 (US).  <b>(74) Agent:</b> OSMAN, Richard, Aron; Science & Technology Law Group, 75 Denise Drive, Hillsborough, CA 94010 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> DIETARY COMPOSITIONS FOR ENHANCING METABOLISM AND ALLEVIATING OXIDATIVE STRESS		
<b>(57) Abstract</b> <p>The metabolic rate of aged cells of a mammalian host is enhanced without a concomitant increase in metabolic production of reactive oxygen species by orally administering to the host an effective dosage of a carnitine, such as acetyl-L-carnitine, and a mitochondrially active antioxidant, such as lipoic acid.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

*Dietary Compositions for Enhancing Metabolism and Alleviating Oxidative Stress*

5 Inventors: Bruce N. Ames and Tory M. Hagen  
Assignee: The Regents of the University of California  
Attorney: Richard Aron Osman (#36,627)

10 This invention was made with Government support under Grant (Contract) Nos.:  
CA39910 and ES01896 awarded by the National Institutes of Health to Professor Bruce  
Ames. The Government has certain rights to this invention.

## INTRODUCTION

Field of the Invention

15 The field of the invention is dietary compositions and methods for modifying both  
cellular metabolism and the metabolic production of reactive oxygen species.

Background of the Invention

20 Numerous lines of evidence suggest that the organelles of cellular respiration, the  
mitochondria, decay with cellular aging (Shigenaga et al. 1994, PNAS 91, 10771).  
Unfortunately, the study of mitochondrial aging has been hampered because mitochondria  
isolated from older cells and host animals are fragile and heterogeneous. Hence the  
interpretation of any results is suspect as about half the mitochondria lyse during  
isolation. Our laboratory recently described a new method for studying mitochondria in  
25 hepatocytes from old animals that avoids this problem (Hagen et al. 1997, PNAS 94,  
3064-3069). We found that mitochondria from older animals are not only more fragile,  
but have about half the level of cardiolipin, a key lipid unique to mitochondria, without  
which they can not maintain a high membrane potential. Furthermore, Hagen et al. show  
that in hepatocytes from older animals, the mitochondria are lower in membrane potential  
30 and leak out more toxic oxidants.

## SUMMARY OF THE INVENTION

We have found that carnitine (a normal mitochondrial metabolite used to transport fatty acids into the mitochondria as fuel) and carnitine derivatives, when put into the drinking water of old animals, restore the cardiolipin and membrane potential of their mitochondria. At the same time, the carnitines increase the flux of reactive oxygen species from the mitochondria. We have found that we can specifically alleviate this enhanced flux with mitochondrially active antioxidants, such as lipoic acid. The two reagents given to old animals, restored all three mitochondrial functions and reversed several gross indicia of aging, including activity, muscle tone, coat appearance and kidney morphology.

Carnitine and carnitine derivatives have been used as metabolites in animal husbandry and for human diet and therapy. US Pat Nos. 5362753 (Method of increasing the hatchability of eggs by feeding hens carnitine); 4687782 (Nutritional composition for enhancing skeletal muscle adaptation to exercise training); 5030458 (Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats); 5030657 (L-carnitine supplemented catfish diet); 4343816 (Pharmaceutical composition comprising an acyl-carnitine, for treating peripheral vascular diseases); 5560928 (Nutritional and/or dietary composition and method of using the same); 5504072 (Enteral nutritional composition having balanced amino acid profile); 5391550 (Compositions of matter and methods for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair); 5240961 (Method of treating reduced insulin-like growth factor and bone loss associated with aging); etc.

Similarly, mitochondrially active antioxidants including vitamins (especially C, E, B and D), glutathione, N-acetyl cysteine, lipoic acid, etc., have been used variously as human nutritional supplements and in dietary prophylaxis and therapy. For example, applications of lipoic acid have include US Pat Nos. 5607980 (Topical compositions having improved skin); 5472698 (Composition for enhancing lipid production in skin); 5292538 (Improved sustained energy and anabolic composition and method of making); 5536645 (Nutritive medium for the culture of microorganisms); 5326699 (Serum-free medium for culturing animal cells); etc.

These reagents, however, have never been administered in the combinations and

dosages necessary to effect enhanced metabolic processes and simultaneously alleviate the resultant increase in oxidative stress. In general, the disclosed methods involve increasing the metabolic rate of aged cells of a mammalian host without a concomitant increase in metabolic production of reactive oxygen species by orally administering to the host an effective dosage of at least about 10 mg/kg host/day of a carnitine and at least about 10 mg/kg host/day of a mitochondrially active antioxidant. In preferred embodiments, the carnitine is acetyl-L-carnitine and the antioxidant comprises a metabolically reactive thiol group and is preferably lipoic acid. The invention also provides orally administratable unit dosages comprising at least about 250 mg/kg host/day of a carnitine and at least about 250 mg/kg host/day of a mitochondrially active antioxidant.

#### DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

Methods for making and preparing carnitine and active carnitine derivatives are known in the art, e.g. US Pat Nos: 4766222 (Novel class of acyl-derivatives of carnitine process for preparing same and therapeutic use thereof); 4673534 (Carnitine salts particularly suitable for oral use); 4743621 (Ester of acetyl carnitine, processes for its preparation and pharmaceutical compositions containing it); 4593043 (Mercapto acyl-carnitines and pharmaceutical compositions containing same); 4590209 (Alkoxy-acyl carnitines and pharmaceutical compositions containing same); 4567200 (Esters of mercapto acyl-carnitines and pharmaceutical compositions containing same); 4032641 (Nicotinoyl carnitine derivatives); 4551477 (Esters of alkoxy-acyl derivatives of carnitine and pharmaceutical compositions containing same); 4401827 (Novel acyl-derivatives of carnitine and process for their preparation); 5260464 (Carnitine derivatives, process for their preparation, and their use in human therapy); 4859698 (Novel class of acyl-derivatives of carnitine, process for preparing same and therapeutic use thereof); 4692543 (Optically-active di-[3-chloro-2-oxy-propyltrimethylammonium]-tartrate); 5258552 (N-alkylamides of d(+)-carnitine having antibacterial activity, process for their preparation and pharmaceutical and cosmetic compositions containing same); etc.

Similarly, a wide variety of mitochondrially active antioxidants (i.e. antioxidants

which reduce the metabolic production of reactive oxygen species, as measured, for example by the oxidant production assay described below) and their methods of formulation, synthesis and production are known. Generally these include physiologically reactive thiols, preferably physiologically reactive sulfhydryl group containing compounds. Exemplary antioxidants include glutathione, NAC, lipoic acid, their derivatives, etc. For example, lipoic acid derivatives and their methods of production are well described, e.g. US Pat Nos. 5621117 (Method for the racemization of enantiomers of .alpha.-lipoic acid); 5489694 (Preparation of R/S-.gamma.-lipoic acid or R/S-.alpha.-lipoic acid); 5463093 (Palladium complexes and methods for using same in the treatment of tumors or Psoriasis); 5334612 (Pharmaceutical compositions containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses); 4390620 (Method and composition for the detection and study of cellular activity or the like and means for applying such method); 5118505 (Combination preparation for the treatment of nerve cell and nerve fibre diseases and injury); 4767704 (Protein-free culture medium), etc. In addition, we have found the R-enantiomeric form of lipoic especially suitable for preferential mitochondrial targeting.

Convenient assays for the requisite bioactivities are described above or in the references cited herein. For example, cardiolipin content is readily assayed as referenced in Guan, Z.Z., Soderberg, M., Sindelar, P., and Edlund, C. *Content and Fatty Acid Composition of Cardiolipin in the Brain of Patients with Alzheimer's Disease*. Neurochem. Int. 25: 295-300, 1994 and oxidant production (DCFH) may be assayed as described by LeBel, C.P., Ischiropoulos, H., and Bondy, S.C. *Evaluation of the Probe 2',7'-Dichlorofluorescein as an Indicator of Reactive Oxygen Species Formation and Oxidative Stress*. Chem. Res. Toxicol. 5: 227-231, 1992. Assays for parameters of aging such as host activity and behavior such as grooming, sexual activity, dominance, etc., coat condition, wound repair, including molecular lesions, muscle strength and tone, kidney appearance and function, etc. are similarly well known in the art.

The invention provides administratively convenient formulations of the compositions including dosage units incorporated into a variety of containers. Dosages of the carnitine and antioxidant are administered orally in the range of about 1 mg/kg to about 1 g/kg, preferably in the range of about 10 mg/kg to about 500 mg/kg more

preferably in the range of about 20 mg/kg to about 200 mg/kg of body weight per day, although variations will necessarily occur depending on the formulation, host, etc. Convenient unit dosage containers and/or formulations include tablets, capsules, lozenges, troches, hard candies, powders, metered sprays, creams, suppositories, etc. The compositions may be combined with a pharmaceutically acceptable excipient such as gelatin, an oil, etc. and/or other pharmaceutically active agent(s). For example, the compositions may be advantageously combined and/or used in combination with other therapeutic or prophylactic agents, different from the subject compounds. In many instances, administration in conjunction with the subject compositions enhances the efficacy of such agents. For example, the compounds may be advantageously used in conjunction with other antioxidants, free radical scavengers; etc.; and mixtures thereof, see e.g. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9<sup>th</sup> Ed., 1996, McGraw-Hill. In another embodiment, the invention provides the subject compounds in the form of one or more pro-drugs, which can be metabolically converted to the subject compounds by the recipient host. A wide variety of pro-drug formulations are known in the art.

The following examples are offered by way of illustration and not by way of limitation.

#### EXAMPLES

Formulation 1. 250 mg pharmaceutical grade dry acetyl-L-carnitine and 250 mg pharmaceutical grade dry lipoic acid are administered orally 4x daily in 500 mg gelatin capsules.

Formulation 2. 500 mg pharmaceutical grade dry acetyl-L-carnitine and 300 mg pharmaceutical grade dry N-acetyl cysteine are administered orally 4x daily in 800 mg gelatin capsules.

Formulation 3. 1% w/v of each pharmaceutical grade acetyl-L-carnitine and pharmaceutical grade glutathione are administered orally in a 2% glucose solution to 0.2 and 0.1 g/kg/day total dosage.

Animal data reveal treated host cell mitochondria demonstrate enhanced levels of cardiolipin and membrane potential, reduced production of reactive oxygen species, and mitigation of indicia of aging, including activity, muscle tone, coat appearance and kidney

morphology.

5 All publications and patent applications cited in this specification are herein  
incorporated by reference as if each individual publication or patent application were  
specifically and individually indicated to be incorporated by reference. Although the  
foregoing invention has been described in some detail by way of illustration and example  
for purposes of clarity of understanding, it will be readily apparent to those of ordinary  
skill in the art in light of the teachings of this invention that certain changes and  
modifications may be made thereto without departing from the spirit or scope of the  
10 appended claims.



## WHAT IS CLAIMED IS:

1. A method for increasing the metabolic rate of aged cells without a concomitant increase in metabolic production of reactive oxygen species, comprising orally administering to a mammalian host an effective dosage of at least about 10 mg/kg host/day of a carnitine and at least about 10 mg/kg host/day of a mitochondrially active antioxidant.
2. The method of claim 1 wherein the carnitine is acetyl-L-carnitine.
3. The method of claim 1 wherein the antioxidant comprises a metabolically reactive thiol group.
4. The method of claim 1 wherein the antioxidant is lipoic acid.
5. The method of claim 1 wherein the carnitine is acetyl-L-carnitine, the antioxidant is lipoic acid and the dosage is at least about 100 mg/kg host/day each.
6. An orally administratable dry unit dosage comprising at least about 250 mg/kg host/day of a carnitine and at least about 250 mg/kg host/day of a mitochondrially active antioxidant.
7. The dosage of claim 6 wherein the carnitine is acetyl-L-carnitine.
8. The dosage of claim 6 wherein the antioxidant comprises a metabolically reactive thiol group.
9. The dosage of claim 6 wherein the antioxidant is lipoic acid.
10. The dosage of claim 6 wherein the carnitine is acetyl-L-carnitine and the antioxidant is lipoic acid.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/12545

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 31/195, 31/385

US CL : 514/440, 561

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/440, 561

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPATFULL, REGISTRY, HCAPLUS, WPIDS, BIOSIS, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,560,928 A (DE FELICE) 01 October 1996, see columns 3-4.	1-10
X	US 5,292,538 A (PAUL et al) 08 March 1994, see column 2.	1-10
X	US 4,599,232 A (BERTELLI) 08 July 1986, see entire document.	1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 JULY 1998

Date of mailing of the international search report

19 AUG 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer,  
*Rebecca Cook*  
Rebecca Cook

Telephone No. (703) 308-1235